Loading...
Market
When will Azitra's ATR-04 enter Phase 3 clinical trials?
2
Resolution / Starting Odds
Q4 2024 • 25%
Q1 2025 • 25%
Q2 2025 • 25%
Q3 2025 or later • 25%
ClinicalTrials.gov and official announcements from Azitra
Story
Azitra Receives FDA Fast Track Designation for ATR-04, Stock Up 10.5%
Sep 18, 2024, 01:02 PM
Azitra, Inc. has received Fast Track designation from the FDA for its drug ATR-04, aimed at treating skin rash caused by EGFR inhibitors. This designation is expected to expedite the development and review process of ATR-04. The company's stock (AZTR) saw a 10.5% increase in pre-market trading following the announcement.
View original story
Similar markets
Yes • 50%
No • 50%
Successful • 50%
Unsuccessful • 50%
Completed successfully • 33%
Ongoing • 34%
Terminated • 33%
Successful with no major adverse effects • 25%
Successful with minor adverse effects • 25%
Unsuccessful due to lack of efficacy • 25%
Unsuccessful due to major adverse effects • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worse outcomes • 25%
Yes • 50%
No • 50%
Initiated before January 1, 2025 • 25%
Initiated between January 1, 2025 and March 31, 2025 • 25%
Initiated between April 1, 2025 and June 30, 2025 • 25%
Not initiated by June 30, 2025 • 25%
